Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have received a consensus rating of “Buy” from the ...

It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and older and in Europe for patients two months of age and older.

Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.

The liver of a child with Alagille syndrome - which is estimated to affect one in 70,000 newborns - has fewer small bile ducts than normal, causing bile to build-up. Symptoms can include yellowing ...

Alagille syndrome (ALGS) is an autosomal dominant disorder characterized by a congenital cholangiopathy of variable severity accompanied by cardiac, skeletal, renal and other abnormalities. In 94% of ...

OrganOx metra for liver transplant [ID5116] Technology appraisal guidance TBC Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111] Technology appraisal guidance TBC ...